Can olive leaf extract reduce the risk of metabolic disease?

Not Applicable

Completed

• Conditions: Insulin sensitivity; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12610001082099
• Lead Sponsor: niversity of Auckland / Liggins Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-12-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

Males aged 35 to 55.
BMI 25 - 30

Exclusion Criteria

Any medications
BMI outside inclusion range
Smokers
Diabetes
Cardiovascular disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin sensitivity. THis will be measured by the Matsuda methodl which is best model compared to the euglycaemic clamp. This involved overnight fasting, with an oral glucose tolerance test. Equipment used will be IV cannulation, and syringes. The Liggins Institute has an in-house assay for insulin level.s[Baseline<br>End of Intervention one (placebo or oleuropein depending in randomization)<br>End of intervention two. (placebo or oleuropein depending in randomization)]